1. 1 WHO Classification of Tumours, Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. (eds): 4th ed, Lyon, IARC, 2008
2. 2 Xu XQ, Wang JM, Gao L, Qiu HY, Chen L, et al.: Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients. Am J Hematol 89:874-881, 2014
3. 3 Najfeld V, Wisch N, Mascarenhas J, Issa L, Tripodi J, et al.: Development of t(8;21) and RUNX1-RUNX1T1 in the Philadelphia-positive clone of a patient with chronic myelogenous leukemia: additional evidence for multiple steps involved in disease progression. Cancer Genet 204:165-170, 2011
4. 4 Komrokji RS, Padron E, Ebert BL, List AF: Deletion 5q MDS: molecular and therapeutic implications. Best Pract Res Clin Haematol 26:365-375, 2013
5. 5 Kuchenbauer F, Schnittger S, Look T, Gilliland G, Tenen D, et al.: Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO. Br J Haematol 134:616-619, 2006